“…Despite advances in our understanding of genetic, environmental, and risk factors of EDs (Barakat et al, 2023), responses to gold-standard outpatient treatments remain modest at best, with large proportions of patients remaining symptomatic decades after being first diagnosed (Couturier et al, 2013;Culbert et al, 2015;Eddy et al, 2017;Kass et al, 2013;Solmi et al, 2024). These issues relate to a number of factors, including an incomplete understanding of the etiological mechanisms driving illness presentations, a paucity of surveillance and large clinical data sets available to guide new discoveries, the presence of contributing comorbid mental health (MH) diagnoses, challenges relating to measurement of clinical and outcome variables, and fragmentation of clinical care that occurs as patients navigate varying intensities of service across different programs (Hay et al, 2019;Norris et al, 2010;Radunz et al, 2020;Touyz et al, 2023;Wade et al, 2024). This may also be due to the recognition that conducting robust research trials of ED treatments is challenging for many reasons (Norris et al, 2007).…”